Announced
Completed
Financials
Tags
Pharmaceuticals
psychiatry
targeted medicines
Acquisition
Minority
Single Bidder
United States
Private Equity
Private
Cross Border
Venture Capital
Completed
Friendly
Synopsis
InVivium Capital, a venture capital firm based in Chicago, led a $45m Series C funding round in Alto Neuroscience, a precision psychiatry developing targeted medicines designed to help patients get better faster, with participation from Franklin Templeton, Point72, Eli Lilly and Company, Alexandria Venture Investments, Alpha Wave Ventures, Lightswitch Capital, Alkeon Capital, WhatIf Ventures, and Windham Venture Partners. “We deeply appreciate the support from investors who fully understand the potential of our precision psychiatry approach, which we believe can help alleviate the significant burden of disease that remains in the treatment of mental health conditions. This financing allows us to bring our clinical programs through key value-generating milestones and significantly extends our operational runway,” Amit Etkin, Alto Neuroscience Founder and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.